Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene

Clinical Microbiology and Infection

Volumn 15, Issue 3, 2009, Pages 238-244

  Hellmark, Bengt ^a   Unemo, M ^a   Nilsdotter augustinsson, A ^b   Soderquist B ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic susceptibility resistance; Prosthetic joint infections; Rifampicin; RpoB; Staphylococcus epidermidis

Indexed keywords

CEFOXITIN; CEFTOBIPROLE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LATAMOXEF; LINEZOLID; MOXIFLOXACIN; NORFLOXACIN; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL ARTICLE; DISK DIFFUSION; ELBOW; EPSILOMETER TEST; GENE IDENTIFICATION; GENETIC VARIABILITY; HIP PROSTHESIS; HUMAN; JOINT PROSTHESIS; KNEE PROSTHESIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION;

STAPHYLOCOCCUS EPIDERMIDIS;

EID: 63249093595     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02663.x     Document Type: Article

References (41)

1. Huebner J, Goldmann DA. Coagulase-negative staphylococci: Role as pathogens. Annu Rev Med 1999; 50: 223-236.
2. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002; 2: 677-685.
3. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-1654.
4. Lidgren L, Knutson K, Stefansdottir A. Infection and arthritis. Infection of prosthetic joints. Best Pract Res Clin Rheumatol 2003; 17: 209-218.
5. Crowe JF, Sculco TP, Kahn B. Revision total hip arthroplasty: Hospital cost and reimbursement analysis. Clin Orthop Relat Res 2003; 413: 175-182.
6. Zavasky DM, Sande MA. Reconsideration of rifampin: A unique drug for a unique infection. JAMA 1998; 279: 1575-1577.
7. Marculescu CE, Berbari EF, Hanssen AD et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis 2006; 42: 471-478.
8. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-1541.
9. Donlan RM. Role of biofilms in antimicrobial resistance. ASAIO J 2000; 46: S47-S52.
10. Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat Res 2005; 437: 41-47.
11. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-193.
12. Trampuz A, Widmer AF. Infections associated with orthopedic implants. Curr Opin Infect Dis 2006; 19: 349-356.
13. Costerton JW. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res 2005; 437: 7-11.
14. Zimmerli W. Infection and musculoskeletal conditions: prosthetic-joint-associated infections. Best Pract Res Clin Rheumatol 2006; 20: 1045-1063.
15. Svensson E, Hanberger H, Nilsson LE. Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing Staphylococcus epidermidis cells. Antimicrob Agents Chemother 1997; 41: 107-111.
16. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in.vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990; 162: 96-102.
17. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-240.
18. Soriano A, Garcia S, Bori G et al. Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbiol Infect 2006; 12: 930-933.
19. Aboltins CA, Page MA, Buising KL et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007; 13: 586-591.
20. Soriano A, Gomez J, Gomez L et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007; 26: 353-356.
21. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008; 27: 3-15.
22. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs 2006; 66: 1089-1105.
23. Feltham RK, Power AK, Pell PA, Sneath PA. A simple method for storage of bacteria at -76 degrees C. J Appl Bacteriol 1978; 44: 313-316.
24. Hellmark B, Söderquist B, Unemo M. Simultaneous species identification and detection of rifampicin resistance in staphylococci by sequencing of the rpoB gene. Eur J Clin Microbiol Infect Dis 2008. [E-pub ahead of print.
25. Berglund C, Mölling P, Sjöberg L, Söderquist B. Predominance of staphylococcal cassette chromosome mec (SCCmec) type.IV among methicillin-resistant Staphylococcus aureus (MRSA) in a Swedish county and presence of unknown SCCmec types with Panton-Valentine leukocidin genes. Clin Microbiol Infect 2005; 11: 447-456.
26. Aubry-Damon H, Soussy CJ, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1998; 42: 2590-2594.
27. O'Neill AJ, Huovinen T, Fishwick CW, Chopra I. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 2006; 50: 298-309.
28. Wichelhaus TA, Schafer V, Brade V, Boddinghaus B. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 2813-2816.
29. Brown DF. Detection of methicillin/oxacillin resistance in staphylococci. J Antimicrob Chemother 2001; 48 (suppl 1): 65S-70S.
30. Milne LM, Curtis GD, Crow M, Kraak WA, Selkon JB. Comparison of culture media for detecting methicillin resistance in Staphylococcus aureus and coagulase negative staphylococci. J Clin Pathol 1987; 40: 1178-1181.
31. Join-Lambert OF, Clauser S, Guillet C et al. Comparison of cefoxitin and moxalactam 30 microg disc diffusion methods for detection of methicillin resistance in coagulase-negative staphylococci. J Antimicrob Chemother 2007; 59: 763-766.
32. Berdal JE, Skramm I, Mowinckel P, Gulbrandsen P, Bjornholt JV. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect 2005; 11: 843-845.
33. Cozza KL, Armstrong SC, Oesterheld JR. Concise guide to drug interaction principles for medical practice, 2nd edn. Arlington: American Psychiatric Publishing, Inc., 2003.
34. Sweetman SC. Martindale: The complete drug reference, 35th edn. London: Pharmaceutical Press, 2006.
35. Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 2003; 31: 878-887.
36. Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of gram-positive prosthetic joint infections. J Antimicrob Chemother 2005; 55: 387-390.
37. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections: A systematic review of the clinical evidence. Int J Antimicrob Agents 2007; 30: 202-209.
38. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-1585.
39. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 5285-5287.
40. Chambers HF. Ceftobiprole: In-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect 2006; 12 (suppl 2): 17S-22S.
41. Decousser JW, Bourgeois-Nicolaos N, Doucet-Populaire F. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 2007; 5: 557-571.